Key result
Pharmacological targeting of monocytes may represent a novel therapeutic approach to treat hypertension and attenuate associated end-organ damage.
Monocytes play a critical role in the initiation and progression of arterial hypertension and represent a potential novel therapeutic target.
Does not support changing hypertension practice; leaves open monocyte targeting for prospective trials.
The role of myelomonocytic cells appears to be critical for the initiation, progression and manifestation of arterial hypertension. Monocytes can induce vascular inflammation as well as tissue remodelling and (mal)adaptation by secreting chemokines and cytokines, producing ROS, expressing coagulation factors and transforming into macrophages. A multitude of adhesion molecules promote the infiltration and accumulation of monocytes into the kidney, heart, brain and vasculature in hypertension. All these facets offer the possibility to pharmacologically target monocytes and may represent novel therapeutic ways to treat hypertension, attenuate hypertension-associated end organ damage or prevent the development or worsening of high blood pressure. LINKED ARTICLES: This article is part of a themed section on Immune Targets in Hypertension. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.12/issuetoc.
No takes yet. Share an insight, caveat, or question.
Philip Wenzel (2018) conducted a review in Arterial hypertension. Pharmacological targeting of monocytes was evaluated. Pharmacological targeting of monocytes may represent a novel therapeutic approach to treat hypertension and attenuate associated end-organ damage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: